



A REVIEW: NANOPARTICLES FOR TOPICAL DELIVERY

Jyoti Srivastava^{1*}, Ankit Singh² and Smriti Mathur³

¹Research Scholar, Advanced Institute of Bio-Tech & Paramedical Sciences, Kanpur, Kanpur, U. P.

²Assistant Professor, Advanced Institute of Bio-Tech & Paramedical Sciences, Kanpur, Kanpur, U. P.

³Assistant Professor, Advanced Institute of Bio-Tech & Paramedical Sciences, Kanpur, Kanpur, U. P.



***Corresponding Author: Jyoti Srivastava**

Research Scholar, Advanced Institute of Bio-Tech & Paramedical Sciences, Kanpur, Kanpur, U. P.

Article Received on 31/07/2024

Article Revised on 20/08/2024

Article Accepted on 09/09/2024

ABSTRACT

Nanoparticles represent a cutting-edge approach in topical delivery systems, offering precise control over drug release kinetics and enhanced permeation through skin barriers. This review explores the diverse applications of nanoparticles across various domains, including dermatological treatments, cosmetic formulations, sunscreen protection, wound healing, transdermal drug delivery, and diagnostic imaging. Nanoparticles facilitate the targeted delivery of therapeutic agents, such as antioxidants, antimicrobials, and growth factors, improving treatment efficacy while minimizing side effects. Their ability to traverse the stratum corneum and deliver payloads directly to skin cells underscores their potential in personalized medicine and skincare. Continued advancements in nanoparticle formulation and characterization promise novel solutions for addressing complex skin conditions and enhancing cosmetic outcomes. This abstract highlights the transformative impact of nanoparticles in advancing topical therapies and shaping the future of skincare and dermatology.

KEYWORDS: Nanoparticles, Topical delivery, Dermatological treatments, Transdermal drug deliver.

I. INTRODUCTION

Nanoparticles are particles that have at least one dimension in the nanometer scale, typically between 1 and 100 nanometers (nm). Due to their small size, nanoparticles exhibit unique physical and chemical properties, such as increased surface area to volume ratio, quantum effects, and enhanced reactivity compared to their bulk counterparts. These properties make nanoparticles particularly useful in various scientific and industrial applications, including drug delivery, imaging, diagnostics, and therapeutics.^[1-2]

Importance of Topical Delivery Systems

Topical delivery systems are crucial in pharmacology and medicine due to their ability to deliver drugs directly to the site of action, thereby enhancing therapeutic efficacy and minimizing systemic side effects. This method is particularly beneficial for treating skin diseases, providing localized treatment for conditions such as eczema, psoriasis, and infections, which ensures higher drug concentrations at the target site compared to systemic delivery.^[3-4] Additionally, topical delivery can bypass the first-pass metabolism in the liver, enhancing the bioavailability of certain drugs. This approach is also non-invasive and generally more patient-friendly, improving adherence to treatment regimens. Moreover, advancements in topical formulations, including the

incorporation of nanoparticles, have further enhanced drug penetration and sustained release, offering new possibilities for treating a wide range of conditions with improved outcomes.^[5-6]

Advantages of Nanoparticles in Topical Delivery

Nanoparticles offer several significant advantages in topical delivery systems, enhancing both the efficacy and safety of therapeutic agents. One of the primary benefits is their ability to improve drug solubility and stability, allowing for the effective delivery of poorly water-soluble drugs. The small size and large surface area of nanoparticles facilitate better penetration through the stratum corneum, the outermost layer of the skin, leading to enhanced drug absorption and bioavailability.^[7]

Furthermore, nanoparticles can provide controlled and sustained drug release, which helps maintain therapeutic drug levels for extended periods, reducing the frequency of application and improving patient compliance. This controlled release also minimizes the risk of side effects associated with peak drug concentrations. Nanoparticles can be engineered to target specific cells or tissues, providing localized treatment and reducing systemic exposure, which is particularly beneficial for treating skin diseases and minimizing systemic side effects.^[8-9]

In addition, nanoparticles can be designed to protect the encapsulated drug from degradation due to environmental factors such as light, heat, and enzymatic activity, thus preserving its therapeutic efficacy. The versatility of nanoparticles allows for the incorporation of multiple therapeutic agents, enabling combination therapy within a single formulation. Lastly, the use of biocompatible and biodegradable materials in nanoparticle formulations ensures safety and minimizes the risk of adverse reactions, making them suitable for long-term use.^[10-11]

II. Types of Nanoparticles Used in Topical Delivery

A. Lipid-Based Nanoparticles

Lipid-based nanoparticles are a class of nanocarriers used for drug delivery that utilize lipids to encapsulate and transport therapeutic agents. These systems are known for their biocompatibility, ability to enhance drug stability, and improve bioavailability. Among the most prominent types are Solid Lipid Nanoparticles (SLNs), Nanostructured Lipid Carriers (NLCs), and Liposomes.

Solid Lipid Nanoparticles (SLNs)

Solid Lipid Nanoparticles are submicron-sized particles composed of solid lipids, which remain solid at both room and body temperatures. SLNs provide a controlled release profile and protection for encapsulated drugs from degradation. They are prepared using various techniques such as high-pressure homogenization and microemulsion methods. SLNs have been extensively studied for their potential in delivering a wide range of drugs, including anticancer agents, antibiotics, and peptides.^[12-13]

Nanostructured Lipid Carriers (NLCs)

Nanostructured Lipid Carriers are an advanced generation of lipid nanoparticles. Unlike SLNs, NLCs consist of a mixture of solid and liquid lipids, which creates an imperfect crystal structure, allowing for higher drug loading and preventing drug expulsion during storage. This characteristic makes NLCs suitable for delivering hydrophobic drugs and enhancing their bioavailability.^[14-15]

Liposomes

Liposomes are spherical vesicles composed of one or more phospholipid bilayers, which can encapsulate both hydrophilic and hydrophobic drugs. They are versatile carriers for drug delivery due to their biocompatibility, ability to encapsulate various drugs, and their potential for targeted delivery. Liposomes can be modified with surface ligands for specific targeting, enhancing their efficacy in drug delivery applications.^[16-17]

B. Polymer-Based Nanoparticles

Polymer-based nanoparticles are another significant class of nanocarriers used in drug delivery systems. These nanoparticles are composed of biocompatible and biodegradable polymers, which can encapsulate a wide range of therapeutic agents. The main types of polymer-

based nanoparticles include polymeric nanoparticles, dendrimers, and nanospheres and nanocapsules.

1. Polymeric Nanoparticles

Polymeric nanoparticles are colloidal particles ranging from 10 to 1000 nm in size, composed of natural or synthetic polymers. These nanoparticles can encapsulate drugs either within the polymer matrix or adsorbed onto the surface. They offer controlled and sustained drug release, improve drug stability, and can be engineered for targeted delivery.^[18]

Advantages^[19]

- Controlled and sustained drug release.
- Enhanced drug stability.
- Ability to encapsulate a wide variety of drugs.
- Potential for targeted delivery.

2. Dendrimers

Dendrimers are highly branched, tree-like polymers with a central core, interior branches, and functional surface groups. These nanoparticles have a well-defined, monodisperse structure and a high degree of surface functionality, making them suitable for drug delivery, especially for targeting and controlled release applications. Their unique structure allows for high drug-loading capacity.^[20]

Advantages^[21]

- High degree of surface functionality for targeted delivery.
- Well-defined and monodisperse structure.
- High drug-loading capacity.
- Ability to encapsulate a variety of therapeutic agents.

3. Nanospheres and Nanocapsules

Nanospheres are solid, spherical polymeric nanoparticles where the drug is uniformly dispersed throughout the polymer matrix. In contrast, nanocapsules are vesicular systems in which the drug is confined to a cavity surrounded by a polymeric shell. Both types of nanoparticles offer controlled drug release and protection for encapsulated drugs.^[22]

Advantages^[23]

- Controlled and sustained drug release.
- Protection for encapsulated drugs.
- Enhanced drug stability and bioavailability.
- Versatile for a wide range of therapeutic agents.

C. Metal-Based Nanoparticles

Metal-based nanoparticles are increasingly utilized in various biomedical applications due to their unique optical, electronic, and catalytic properties. These nanoparticles are typically composed of metals like silver, gold, and zinc oxide, each offering distinct advantages for drug delivery and therapeutic purposes.

1. Silver Nanoparticles

Silver nanoparticles (AgNPs) are widely recognized for their potent antimicrobial properties. These nanoparticles have been used extensively in wound dressings, coatings for medical devices, and topical creams. Silver nanoparticles exert their antimicrobial effect by releasing silver ions, which disrupt microbial cell membranes, proteins, and DNA.^[24]

Advantages^[25]

- Broad-spectrum antimicrobial activity.
- Potential to enhance wound healing.
- Anti-inflammatory properties.
- Synergistic effects when combined with antibiotics.

2. Gold Nanoparticles

Gold nanoparticles (AuNPs) are known for their biocompatibility and ease of functionalization. These nanoparticles have unique optical properties, such as surface plasmon resonance, which can be utilized for imaging, diagnostics, and photothermal therapy. Gold nanoparticles can be used to deliver drugs, genes, and other therapeutic agents directly to target cells.^[26]

Advantages^[27]

- Biocompatibility and low toxicity.
- Easy functionalization for targeted delivery.
- Optical properties for imaging and diagnostics.
- Applications in photothermal therapy.

3. Zinc Oxide Nanoparticles

Zinc oxide nanoparticles (ZnO NPs) are used in various biomedical applications due to their antibacterial, antifungal, and UV-blocking properties. These nanoparticles are also known for their biocompatibility and are used in cosmetics, sunscreens, and topical formulations. ZnO nanoparticles can enhance wound healing and provide antimicrobial protection.^[28]

Advantages^[29]

- Antibacterial and antifungal properties.
- UV-blocking capabilities.
- Biocompatibility.
- Enhancement of wound healing.

D. Hybrid Nanoparticles

Hybrid nanoparticles are composed of two or more different materials, combining the advantages of each component to create multifunctional systems for enhanced drug delivery and therapeutic applications. These nanoparticles can integrate organic and inorganic materials, offering unique properties such as improved drug loading, controlled release, targeting capabilities, and diagnostic functions.^[30]

Definition and Composition

Hybrid nanoparticles typically consist of a core material, which can be organic (e.g., polymers, lipids) or inorganic (e.g., metals, silica), surrounded by a shell or matrix of a

different material. This combination allows for the incorporation of diverse functionalities, such as magnetic, optical, and therapeutic properties, within a single nanoparticle.^[30]

Advantages^[31]

- Enhanced drug loading capacity and stability.
- Controlled and sustained drug release.
- Targeted delivery and reduced side effects.
- Multifunctional capabilities for combined therapeutic and diagnostic (theranostic) applications.

Types of Hybrid Nanoparticles

1. Polymer-Metal Hybrid Nanoparticles

Polymer-metal hybrid nanoparticles combine the biocompatibility and flexibility of polymers with the unique properties of metals, such as their optical, electrical, and magnetic characteristics. These nanoparticles are used in various applications, including targeted drug delivery, imaging, and photothermal therapy.^[32]

2. Lipid-Polymer Hybrid Nanoparticles

Lipid-polymer hybrid nanoparticles consist of a polymer core encapsulated by a lipid layer, combining the advantages of both lipid-based and polymer-based systems. These nanoparticles offer high drug loading, stability, and controlled release, making them ideal for delivering hydrophobic and hydrophilic drugs.^[33]

3. Metal-Silica Hybrid Nanoparticles

Metal-silica hybrid nanoparticles typically consist of a metal core (e.g., gold, silver) surrounded by a silica shell. The silica shell provides stability, biocompatibility, and functionalization possibilities, while the metal core offers unique optical and electronic properties. These nanoparticles are used in imaging, diagnostics, and drug delivery.^[34]

4. Organic-Inorganic Hybrid Nanoparticles

Organic-inorganic hybrid nanoparticles combine organic materials (e.g., polymers, lipids) with inorganic materials (e.g., metals, silica), creating versatile platforms for drug delivery and theranostics. These nanoparticles can be engineered to possess multifunctional capabilities, such as drug delivery, imaging, and therapeutic effects.^[35]

III. Methods of Preparation

A. Top-Down Approaches

Milling involves the mechanical grinding or pulverization of coarse materials into nanoparticles using techniques such as ball milling, attrition milling, and planetary milling. This process subjects coarse particles to mechanical forces that fracture and reduce them to nanoparticle size. Milling is widely utilized in nanoparticle synthesis due to its scalability and ability to precisely control particle size and distribution. It is an essential method in various applications such as drug delivery, where uniform particle size plays a critical role in therapeutic efficacy.^[36]

High-pressure homogenization is a method used to produce nanoparticles by forcing coarse materials through a narrow gap at high pressures. This process applies mechanical shear forces and cavitation effects to break down larger particles into smaller nanoparticles. High-pressure homogenization is known for its effectiveness in achieving uniform particle size distribution and producing stable colloidal suspensions. It is particularly suitable for applications involving heat-sensitive materials, making it valuable in pharmaceutical formulations and biotechnological processes.^[37]

B. Bottom-Up Approaches

Solvent evaporation is a widely used method to prepare nanoparticles, particularly lipid-based and polymer-based nanoparticles. In this approach, a polymer or lipid dissolved in a volatile organic solvent is emulsified in an aqueous phase containing a surfactant. The organic solvent is then evaporated under reduced pressure or at elevated temperatures, leading to the formation of nanoparticles. The size of the nanoparticles can be controlled by varying parameters such as the concentration of polymer or lipid, type of organic solvent, and the method of emulsification. Solvent evaporation is advantageous for encapsulating hydrophobic drugs and biomolecules due to its gentle processing conditions and ability to maintain the stability of sensitive compounds.^[38-39]

Nano-precipitation

Nano-precipitation, also known as solvent displacement or solvent diffusion, is a technique used to prepare nanoparticles by mixing a polymer solution in an organic solvent with an anti-solvent (typically water) under controlled conditions. The rapid diffusion of the anti-solvent into the polymer solution induces precipitation and formation of nanoparticles. This method allows for the preparation of nanoparticles with narrow size distribution and is suitable for both hydrophobic and hydrophilic drugs. Nano-precipitation offers advantages such as simplicity, scalability, and the ability to encapsulate a wide range of therapeutic agents.^[40-41]

IV. Characterization of Nanoparticles

A. Particle Size and Distribution

Particle size and distribution are critical parameters in nanoparticle characterization, influencing their stability, drug loading capacity, and biological interactions. Techniques such as dynamic light scattering (DLS), scanning electron microscopy (SEM), and nanoparticle tracking analysis (NTA) are commonly used to determine the size distribution of nanoparticles. By analyzing particle size, researchers can ensure uniformity and optimize formulations for specific applications, such as targeted drug delivery or imaging agents.^[42]

B. Surface Charge (Zeta Potential)

The surface charge, or zeta potential, of nanoparticles plays a vital role in their stability and interaction with biological systems. Zeta potential indicates the

electrostatic repulsion between particles, affecting aggregation and colloidal stability. Techniques like electrophoretic light scattering (ELS) are used to measure zeta potential. Nanoparticles with high absolute values of zeta potential (positive or negative) exhibit greater stability due to increased repulsive forces, crucial for applications where stability in biological fluids or controlled release is essential.^[43]

C. Morphology and Structure

Understanding the morphology and structure of nanoparticles is crucial for assessing their physical properties and functionality. Transmission electron microscopy (TEM), atomic force microscopy (AFM), and SEM are used to visualize nanoparticle morphology at high resolution. These techniques reveal details such as shape, surface characteristics, and internal structure, providing insights into how these properties influence biological interactions, drug encapsulation efficiency, and release kinetics.^[44]

D. Encapsulation Efficiency

Encapsulation efficiency measures the percentage of drug or payload effectively entrapped within nanoparticles during formulation. It is assessed using analytical techniques like UV-Vis spectroscopy or HPLC to quantify the amount of drug loaded versus the total amount used in formulation. High encapsulation efficiency indicates effective drug loading and protection, essential for optimizing therapeutic efficacy and minimizing side effects in drug delivery systems.^[45]

E. Drug Release Profiles

The drug release profile from nanoparticles determines the kinetics of drug release over time, critical for controlling therapeutic efficacy and dosage regimen. Release profiles are typically studied using *in vitro* dissolution tests under physiological conditions, monitoring the cumulative release of drug from nanoparticles. Factors influencing release include nanoparticle composition, size, and surface properties. Understanding drug release profiles helps in tailoring formulations for sustained, controlled, or targeted drug delivery applications.^[46]

V. Mechanisms of Skin Penetration

A. Stratum Corneum Penetration

Stratum corneum penetration is a crucial pathway for drug delivery through the skin. The stratum corneum, the outermost layer of the epidermis, consists of densely packed keratinocytes embedded in a lipid matrix. Small molecules can penetrate this barrier through passive diffusion or with the aid of penetration enhancers. Understanding stratum corneum penetration is essential for designing effective topical formulations.^[47]

B. Transappendageal Route

The transappendageal route involves drug penetration through hair follicles and sweat glands. Hair follicles extend through the epidermis and dermis, providing a

pathway for molecules to reach deeper skin layers. This route is significant for enhancing drug delivery to the dermal and subcutaneous layers, bypassing the stratum corneum barrier.^[48]

C. Intercellular Lipid Pathway

The intercellular lipid pathway involves drug diffusion through the lipid bilayers between keratinocytes in the stratum corneum. Lipid-based nanoparticles and vesicles exploit this pathway to deliver drugs deeper into the skin layers. Understanding lipid interactions and lipid

organization in the stratum corneum is crucial for optimizing lipid-based formulations.^[49]

D. Intracellular Pathway

The intracellular pathway involves drug uptake by keratinocytes and other skin cells. Nanoparticles and carrier systems can facilitate cellular uptake through endocytosis or direct membrane fusion. This pathway allows for targeted delivery of drugs to specific skin cells, influencing therapeutic efficacy and minimizing systemic side effects.^[50]

VI. Factors Influencing Topical Delivery of Nanoparticles

Factor	Description	Influence on Topical Delivery
Nanoparticle Properties	Size, shape, surface charge, and composition influence skin penetration and interaction with biological barriers.	Particle size affects depth of penetration; surface charge affects stability and interaction with skin; composition dictates drug release kinetics. ^[51]
Skin Barrier Function	The integrity and hydration state of the stratum corneum affect nanoparticle penetration.	Impaired barrier allows deeper penetration; hydration enhances permeability of nanoparticles. ^[52]
Formulation Components	Excipients, surfactants, and penetration enhancers influence stability, solubility, and skin permeation of nanoparticles.	Excipients stabilize nanoparticles; surfactants enhance solubility; penetration enhancers improve skin penetration efficiency. ^[53]
Application Method	Technique and frequency of application affect nanoparticle deposition and absorption into the skin.	Proper application ensures uniform coverage; frequency affects cumulative dosage delivered. ^[54]
Skin Microenvironment	pH, temperature, and moisture levels in the skin influence nanoparticle stability and interaction with skin barriers.	pH affects stability; temperature alters skin permeability; moisture levels influence hydration and penetration. ^[55]
Targeting Strategies	Surface modifications or ligand conjugation on nanoparticles can enhance specific targeting to skin cells or tissues.	Targeting ligands increase specificity; surface modifications improve cellular uptake and tissue retention. ^[56]

CONCLUSION

In conclusion, Nanoparticles have revolutionized topical delivery systems, offering enhanced therapeutic efficacy and targeted cosmetic benefits through precise control over drug release and improved skin penetration. Their applications span across dermatological treatments, cosmetic formulations, sunscreen protection, wound healing, transdermal drug delivery, and diagnostic imaging, each leveraging nanoparticles' unique properties to optimize treatment outcomes. By overcoming barriers like the stratum corneum and enhancing bioavailability, nanoparticles pave the way for innovative solutions in personalized medicine and skincare. Continued research into nanoparticle formulations and their interactions with biological systems holds promise for future advancements in topical therapies, ensuring safer, more effective treatments for diverse skin conditions and cosmetic needs.

ACKNOWLEDGEMENT

We express our sincere gratitude to all authors contributed to the completion of this paper.

Conflict of Interest

No authors declared Conflict of Interest.

REFERENCES

- Buzea, C., Pacheco, I. I., & Robbie, K. (2007). Nanomaterials and nanoparticles: Sources and toxicity. *Biointerphases*, 2(4): MR17-MR71. <https://doi.org/10.1116/1.2815690>
- Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M., & Rizzolio, F. (2019). The history of nanoscience and nanotechnology: From chemical-physical applications to nanomedicine. *Molecules*, 25(1): 112. <https://doi.org/10.3390/molecules25010112>
- Benson, H. A. E. (2005). Transdermal drug delivery: Penetration enhancement techniques. *Current Drug Delivery*, 2(1): 23-33. <https://doi.org/10.2174/1567201052772915>
- Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology*, 26(11): 1261-1268. <https://doi.org/10.1038/nbt.1504>
- Yadav V.K, Rai A.K., Ghosh A. K.: Encapsulation of Repaglinide into Eudragit RS Microspheres and modulation of Their Release Characteristics by use of Surfactants. *International Journal of Pharmaceutical Sciences and research*, 2017; 8(9): 3936-3947.
- Elias, P. M. (2005). Stratum corneum defensive functions: An integrated view. *Journal of Investigative Dermatology*, 125(2): 183-200. <https://doi.org/10.1111/j.0022-202X.2005.23668.x>

7. Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences*, 14(2): 101-114. [https://doi.org/10.1016/S0928-0987\(01\)00167-1](https://doi.org/10.1016/S0928-0987(01)00167-1)
8. Fang, J. Y., & Leu, Y. L. (2006). Enhanced delivery of tea catechins and polyphenols by EGCG nanoparticles in the skin. *Journal of Pharmaceutical Sciences*, 95(6): 1333-1342. <https://doi.org/10.1002/jps.20591>
9. Raghuvanshi, D., & Misra, A. (2017). Nano-engineered strategies for the delivery of antipsoriatic therapeutics. *Therapeutic Delivery*, 8(1): 9-12. <https://doi.org/10.4155/tde-2016-0067>
10. Liu, P., & Zhang, L. (2011). Enhancement of skin permeation of docetaxel: A novel approach combining microneedle and nanoparticles. *Journal of Controlled Release*, 151(2): 124-132. <https://doi.org/10.1016/j.jconrel.2010.12.014>
11. Korting, H. C., Schäfer-Korting, M., & Mutschler, E. (1999). Principles of topical therapy. In E. Mutschler & M. Schäfer-Korting (Eds.), *Dermatopharmacology of Topical Preparations* (pp. 1-27). Springer.
12. Yadav V. K, Rai A.K., Ghosh A. K: "A study on the effects of different surfactants on morphology and drug release of Repaglinide Microspheres" *International Journal of Research and Development in Pharmacy & Life Science*, 2017; 6(5): 2786-2792.
13. Prow, T. W., Grice, J. E., Lin, L. L., Faye, R., Butler, M., Becker, W., & Roberts, M. S. (2011). Nanoparticles and microparticles for skin drug delivery. *Advanced Drug Delivery Reviews*, 63(6): 470-491. <https://doi.org/10.1016/j.addr.2011.01.012>
14. Muller, R. H., Radtke, M., & Wissing, S. A. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. *Advanced Drug Delivery Reviews*, 54(S1): S131-S155. [https://doi.org/10.1016/S0169-409X\(02\)00118-7](https://doi.org/10.1016/S0169-409X(02)00118-7)
15. Mehnert, W., & Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. *Advanced Drug Delivery Reviews*, 47(2-3): 165-196. [https://doi.org/10.1016/S0169-409X\(01\)00105-3](https://doi.org/10.1016/S0169-409X(01)00105-3)
16. Muller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1): 161-177. [https://doi.org/10.1016/S0939-6411\(00\)00087-4](https://doi.org/10.1016/S0939-6411(00)00087-4)
17. Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Prêat, V. (2016). Nanostructured lipid carriers: Promising drug delivery systems for future clinics. *Nanomedicine: Nanotechnology, Biology and Medicine*, 12(1): 143-161. <https://doi.org/10.1016/j.nano.2015.09.004>
18. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1): 36-48. <https://doi.org/10.1016/j.addr.2012.09.037>
19. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. *Nature Reviews Drug Discovery*, 4(2): 145-160. <https://doi.org/10.1038/nrd1632>
20. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. *Journal of Controlled Release*, 70(1-2): 1-20. [https://doi.org/10.1016/S0168-3659\(00\)00339-4](https://doi.org/10.1016/S0168-3659(00)00339-4)
21. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Prêat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release*, 161(2): 505-522. <https://doi.org/10.1016/j.jconrel.2012.01.043>
22. Kesharwani, P., Jain, K., & Jain, N. K. (2014). Dendrimer as nanocarrier for drug delivery. *Progress in Polymer Science*, 39(2): 268-307. <https://doi.org/10.1016/j.progpolymsci.2013.07.005>
23. Gillies, E. R., & Frechet, J. M. J. (2005). Dendrimers and dendritic polymers in drug delivery. *Drug Discovery Today*, 10(1): 35-43. [https://doi.org/10.1016/S1359-6446\(04\)03276-3](https://doi.org/10.1016/S1359-6446(04)03276-3)
24. Panyam, J., & Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Advanced Drug Delivery Reviews*, 55(3): 329-347. [https://doi.org/10.1016/S0169-409X\(02\)00228-4](https://doi.org/10.1016/S0169-409X(02)00228-4)
25. Quintanar-Guerrero, D., Fessi, H., Allémann, E., Doelker, E., & Anderson, J. M. (1998). Influence of stabilizing agents and preparative variables on the formation of poly(D,L-lactic acid) nanoparticles by an emulsification-diffusion technique. *International Journal of Pharmaceutics*, 143(1): 133-141. [https://doi.org/10.1016/S0378-5173\(96\)04872-9](https://doi.org/10.1016/S0378-5173(96)04872-9)
26. Rai, M., Yadav, A., & Gade, A. (2009). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances*, 27(1): 76-83. <https://doi.org/10.1016/j.biotechadv.2008.09.002>
27. Pal, S., Tak, Y. K., & Song, J. M. (2007). Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium *Escherichia coli*. *Applied and Environmental Microbiology*, 73(6): 1712-1720. <https://doi.org/10.1128/AEM.02218-06>
28. Dreaden, E. C., Mackey, M. A., Huang, X., Kang, B., & El-Sayed, M. A. (2011). Beating cancer in multiple ways using nanogold. *Chemical Society Reviews*, 40(7): 3391-3404. <https://doi.org/10.1039/c0cs00180e>
29. Jain, P. K., Huang, X., El-Sayed, I. H., & El-Sayed, M. A. (2008). Noble metals on the nanoscale: Optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. *Accounts of Chemical Research*, 41(12): 1578-1586. <https://doi.org/10.1021/ar7002804>

30. Raghupathi, K. R., Koodali, R. T., & Manna, A. C. (2011). Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles. *Langmuir*, 27(7): 4020-4028. <https://doi.org/10.1021/la104825u>
31. Espitia, P. J. P., Soares, N. D. F. F., Coimbra, J. S. D. R., de Andrade, N. J., Cruz, R. S., & Medeiros, E. A. A. (2012). Zinc oxide nanoparticles: Synthesis, antimicrobial activity and food packaging applications. *Food and Bioprocess Technology*, 5(5): 1447-1464. <https://doi.org/10.1007/s11947-012-0797-6>
32. Gao, J., Gu, H., & Xu, B. (2009). Multifunctional magnetic nanoparticles: Design, synthesis, and biomedical applications. *Accounts of Chemical Research*, 42(8): 1097-1107. <https://doi.org/10.1021/ar9000026>
33. Sanvicens, N., & Marco, M. P. (2008). Multifunctional nanoparticles—properties and prospects for their use in human medicine. *Trends in Biotechnology*, 26(8): 425-433. <https://doi.org/10.1016/j.tibtech.2008.04.005>
34. Yang, J., Lee, C. H., Ko, H. J., Suh, J. S., Yoon, H. G., Lee, K., & Huh, Y. M. (2007). Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. *Angewandte Chemie International Edition*, 46(46): 8836-8839. <https://doi.org/10.1002/anie.200702225>
35. Zhang, L., Chan, J. M., & Gu, F. X. (2008). Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. *ACS Nano*, 2(8): 1696-1702. <https://doi.org/10.1021/nn800275r>
36. Liz-Marzán, L. M. (2006). Tailoring surface plasmons through the morphology and assembly of metal nanoparticles. *Langmuir*, 22(1), 32-41. <https://doi.org/10.1021/la0513353>
37. Guo, S., & Huang, L. (2011). Nanoparticles escaping RES and endosome: Challenges for siRNA delivery for cancer therapy. *Journal of Nanomaterials*, 2011; 742895. <https://doi.org/10.1155/2011/742895>
38. Khalid, N., Fazal, S., & Othman, Z. A. (2014). *Nanotechnology from A to Z: Applications of nanoparticles*. CRC Press.
39. Müller, R. H., & Keck, C. M. (2004). Challenges and solutions for the delivery of biotech drugs — a review of drug nanocrystal technology and lipid nanoparticles. *Journal of Biotechnology*, 113(1-3): 151-170. <https://doi.org/10.1016/j.jbiotec.2004.04.012>
40. Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., & Benita, S. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. *International Journal of Pharmaceutics*, 55(1): R1-R4. [https://doi.org/10.1016/0378-5173\(89\)90281-0](https://doi.org/10.1016/0378-5173(89)90281-0)
41. Mainardes, R. M., & Evangelista, R. C. (2005). PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. *International Journal of Pharmaceutics*, 290(1-2): 137-144. <https://doi.org/10.1016/j.ijpharm.2004.11.018>
42. Fessi, H., Puisieux, F., Devissaguet, J. P., & Ammoury, N. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. *International Journal of Pharmaceutics*, 55(1): R1-R4. [https://doi.org/10.1016/0378-5173\(89\)90281-0](https://doi.org/10.1016/0378-5173(89)90281-0)
43. Huynh, C. T., Nguyen, M. K., & Tran, N. Q. (2012). Preparation of nanoparticles via nanoprecipitation method. In T. T. T. Nguyen & N. Q. Tran (Eds.), *Nanoparticulates as Drug Carriers* (pp. 37-69). Elsevier. <https://doi.org/10.1016/B978-0-12-391860-7.00002-4>
44. Torchilin, V. P. (2007). Nanoparticulates as Drug Carriers. In *Pharmaceutical Nanotechnology*, 53: 63-73). Springer. https://doi.org/10.1007/978-1-4020-6118-9_4
45. Chiesa, E., Dorati, R., Modena, T., Conti, B., Genta, I., & Bruni, G. (2018). Zeta potential: A key parameter for nanotechnology-based drug delivery systems. *Journal of Nanoparticle Research*, 20(8): 240. <https://doi.org/10.1007/s11051-018-4301-3>
46. Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., & Napier, M. E. (2008). The effect of particle design on cellular internalization pathways. *Proceedings of the National Academy of Sciences*, 105(33): 11613-11618. <https://doi.org/10.1073/pnas.0801763105>
47. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., Préat, V., & Lecomte, F. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release*, 161(2): 505-522. <https://doi.org/10.1016/j.jconrel.2012.01.043>
48. Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Molecular Pharmaceutics*, 5(4): 505-515. <https://doi.org/10.1021/mp800051m>
49. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology*, 26(11): 1261-1268. <https://doi.org/10.1038/nbt.1504>
50. Otberg, N., Patzelt, A., Rasulev, U., Hagemester, T., Linscheid, M., Sinkgraven, R., Sterry, W., & Lademann, J. (2008). The role of hair follicles in the percutaneous absorption of caffeine. *British Journal of Clinical Pharmacology*, 65(4): 488-492. <https://doi.org/10.1111/j.1365-2125.2007.03008.x>
51. Elias, P. M. (2005). Stratum corneum defensive functions: An integrated view. *Journal of Investigative Dermatology*, 125(2): 183-200. <https://doi.org/10.1111/j.0022-202X.2005.23768.x>
52. Benson, H. A. (2006). Transfersomes for transdermal drug delivery. *Expert Opinion on Drug Delivery*, 3(6): 727-737. <https://doi.org/10.1517/17425247.3.6.727>
53. Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., & Napier, M. E. (2008).

- Proceedings of the National Academy of Sciences, 105(33): 11613-11618.
54. Elias, P. M. (2005). *Journal of Investigative Dermatology*, 125(2): 183-200.
 55. Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001). *Pharmacological Reviews*, 53(2): 283-318.
 56. Rawlings, A. V., & Davies, A. (2006). *International Journal of Cosmetic Science*, 28(6): 359-370.
 57. Hadgraft, J., & Lane, M. E. (2016). *European Journal of Pharmaceutical Sciences*, 89: 82-89
 58. Illum, L. (2004). *Journal of Controlled Release*, 100(1): 75-88.